HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.